3 Inflated Stocks We Approach with Caution

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

While momentum can be a leading indicator, it has burned many investors as it doesn’t always correlate with long-term success. Keeping that in mind, here are three overhyped stocks that may correct and some you should consider instead.

BJ's (BJRI)

One-Month Return: +13%

Founded in 1978 in California, BJ’s Restaurants (NASDAQ:BJRI) is a chain of restaurants whose menu features classic American dishes, often with a twist.

Why Are We Out on BJRI?

1. Disappointing same-store sales over the past two years show customers aren’t responding well to its menu offerings and dining experience
2. Gross margin of 14.7% is below its competitors, leaving less money for marketing and promotions
3. ROIC of 3% reflects management’s challenges in identifying attractive investment opportunities

BJ’s stock price of $45.53 implies a valuation ratio of 19.9x forward P/E. If you’re considering BJRI for your portfolio, see our FREE research report to learn more.

Griffon (GFF)

One-Month Return: +10.9%

Initially in the defense industry, Griffon (NYSE:GFF) is a now diversified company specializing in home improvement, professional equipment, and building products.

Why Does GFF Worry Us?

1. Annual sales declines of 3.1% for the past two years show its products and services struggled to connect with the market during this cycle
2. Sales are projected to be flat over the next 12 months and imply weak demand

Griffon is trading at $85.20 per share, or 14x forward P/E. Dive into our free research report to see why there are better opportunities than GFF.

Illumina (ILMN)

One-Month Return: +10.3%

Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina (NASDAQ:ILMN) develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions.

Why Are We Cautious About ILMN?

1. Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
2. Revenue growth over the past five years was nullified by the company’s new share issuances as its earnings per share fell by 2.2% annually
3. Low returns on capital reflect management’s struggle to allocate funds effectively

At $145.06 per share, Illumina trades at 29.2x forward P/E. Check out our free in-depth research report to learn more about why ILMN doesn’t pass our bar.

Stocks We Like More

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.